Assignee
JUNO THERAPEUTICS INC
US·62 granted patents·110 pending applications·175 citations·filing 2015–2025
Top patents by PatentIndex Score
172 records- 0194US12208137B2Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2023·Granted Jan 28, 2025·4 cites·10 claims
- 0294US11400115B2Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Aug 2, 2022·18 cites·28 claims
- 0394US10738278B2Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Aug 11, 2020·8 cites·21 claims
- 0493US12296010B2Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·1 cites·20 claims
- 0593US10889652B2Antibodies and chimeric antigen receptors specific for ROR1JUNO THERAPEUTICS INC·Filed 2018·Granted Jan 12, 2021·9 cites·29 claims
- 0692US11944647B2Articles of manufacture and methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2022·Granted Apr 2, 2024·5 cites·20 claims
- 0792US11413310B2Articles of manufacture and methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2018·Granted Aug 16, 2022·12 cites·55 claims
- 0892US10533055B2Antibodies and chimeric antigen receptors specific for CD19JUNO THERAPEUTICS INC·Filed 2015·Granted Jan 14, 2020·16 cites·48 claims
- 0991US11066475B2Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotidesJUNO THERAPEUTICS INC·Filed 2018·Granted Jul 20, 2021·10 cites·23 claims
- 1090US10507219B2Methods and compositions for dosing in adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Dec 17, 2019·10 cites·38 claims
- 1190US2025387482A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1289US11623961B2Antibodies and chimeric antigen receptors specific for B-cell maturation antigenJUNO THERAPEUTICS INC·Filed 2018·Granted Apr 11, 2023·7 cites·35 claims
- 1389US10786533B2Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·4 cites·24 claims
- 1488US11020429B2Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Jun 1, 2021·9 cites·49 claims
- 1587US12193994B2Combination of a cell therapy and a gamma secretase inhibitorJUNO THERAPEUTICS INC·Filed 2018·Granted Jan 14, 2025·4 cites·32 claims
- 1687US10428351B2Methods for transduction and cell processingJUNO THERAPEUTICS INC·Filed 2015·Granted Oct 1, 2019·13 cites·42 claims
- 1787US10363269B2Modified hepatitis post-transcriptional regulatory elementsJUNO THERAPEUTICS INC·Filed 2016·Granted Jul 30, 2019·8 cites·46 claims
- 1886US11919970B2Antibodies and chimeric antigen receptors specific for ROR1JUNO THERAPEUTICS INC·Filed 2020·Granted Mar 5, 2024·1 cites·40 claims
- 1986US11851678B2Methods for producing genetically engineered cell compositions and related compositionsJUNO THERAPEUTICS INC·Filed 2018·Granted Dec 26, 2023·9 cites·38 claims
- 2085US12215348B2Methods for producing genetically engineered cell compositions and related compositionsJUNO THERAPEUTICS INC·Filed 2023·Granted Feb 4, 2025·1 cites·26 claims
- 2185US11072660B2HPV-specific binding moleculesJUNO THERAPEUTICS INC·Filed 2017·Granted Jul 27, 2021·4 cites·34 claims
- 2283US11815514B2Methods and compositions related to toxicity associated with cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Nov 14, 2023·2 cites·31 claims
- 2383US11633426B2Methods and compositions for dosing in adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2019·Granted Apr 25, 2023·1 cites·43 claims
- 2483US11266739B2Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Mar 8, 2022·2 cites·45 claims
- 2583US2025312446A1Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2682US12583904B2Articles of manufacture and methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2024·Granted Mar 24, 2026·0 cites·18 claims
- 2782US2024066122A1Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2881US11561219B2Methods of enumerating particles present in a cell compositionJUNO THERAPEUTICS INC·Filed 2017·Granted Jan 24, 2023·3 cites·26 claims
- 2980US11564946B2Methods associated with tumor burden for assessing response to a cell therapyJUNO THERAPEUTICS INC·Filed 2018·Granted Jan 31, 2023·2 cites·40 claims
- 3080US2023090176A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3178US2024115612A1Articles of manufacture and methods for treatment using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3278US2024368625A1Methods and compositions for preparing genetically engineered cellsJUNO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3376US12168027B2Methods associated with tumor burden for assessing response to a cell therapyJUNO THERAPEUTICS INC·Filed 2022·Granted Dec 17, 2024·0 cites·37 claims
- 3476US11590167B2Methods and compositions for use of therapeutic T cells in combination with kinase inhibitorsJUNO THERAPEUTICS INC·Filed 2017·Granted Feb 28, 2023·2 cites·37 claims
- 3576US11535903B2Methods and reagents for assessing the presence or absence of replication competent virusJUNO THERAPEUTICS INC·Filed 2019·Granted Dec 27, 2022·2 cites·25 claims
- 3676US11421287B2Methods for assessing the presence or absence of replication competent virusJUNO THERAPEUTICS INC·Filed 2017·Granted Aug 23, 2022·1 cites·35 claims
- 3776US2024018256A1Antibodies and chimeric antigen receptors specific for cd19JUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3875US12161670B2Phenotypic markers for cell therapy and related methodsJUNO THERAPEUTICS INC·Filed 2018·Granted Dec 10, 2024·1 cites·20 claims
- 3975US2025152712A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4075US2024151713A1Articles of manufacture and methods related to toxicity associated with cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4175US2022280642A1Methods and compositions for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4275US2025161450A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4375US2023285463A1Methods and compositions for dosing in adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4475US2025161449A1Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4574US12379375B2Methods for assessing cell surface glycosylationJUNO THERAPEUTICS INC·Filed 2023·Granted Aug 5, 2025·0 cites·18 claims
- 4674US11827714B2Antibodies and chimeric antigen receptors specific for CD19JUNO THERAPEUTICS INC·Filed 2019·Granted Nov 28, 2023·0 cites·31 claims
- 4773US2024011051A1Methods for transduction and cell processingJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4873US2025090542A1Combination of a cell therapy and a gamma secretase inhibitorJUNO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4972US12258580B2Process for generating therapeutic compositions of engineered cellsJUNO THERAPEUTICS INC·Filed 2018·Granted Mar 25, 2025·2 cites·41 claims
- 5072US11952408B2HPV-specific binding moleculesJUNO THERAPEUTICS INC·Filed 2018·Granted Apr 9, 2024·1 cites·46 claims
Showing the top 50 of 172 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →